Update in the treatment of chronic hepatitis B;Actualización en el tratamiento de la hepatitis crónica B

Gastroenterologia y Hepatologia

Volumn 27, Issue 2, 2004, Pages 55-57

  Buti, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; CHRONIC HEPATITIS; DNA DETERMINATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ERADICATION THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; INCIDENCE; LIVER CANCER; LIVER FIBROSIS; NONHUMAN; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; SEROCONVERSION; SIDE EFFECT; VIRUS REPLICATION;

EID: 1442325575     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13056427     Document Type: Editorial

References (12)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
2. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-6.
3. Rosenberg PM, Dienstag JL. Therapy with nucleoside analogues for hepatitis B virus infection. Clin Liver Dis 1999;3:349-60.
4. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: summary of a workshop. Gastroenterology 2001;120:1828-53.
5. Dienstag JL, Schiff ER, Wight TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
6. Liaw Y-F, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
7. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96.
8. Stuyver LJ, Locarnini S A, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-7.
9. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1999;29:151-68.
10. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Siffman M, et al. Adefovir dipivoxil for the treatment of patients hepatitis B e antigen positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
11. Hadziyannis S, Tassopoulos N, Heathcote J, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of patients hepatitis B e antigen negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
12. Peters M, Hann HW, Martin P, Heathcote E, Buggisch P, Moorat AE, et al. Adefovir dipivoxil alone and in combination with lamivudine suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis. Hepatology 2002;36;374A.